• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    PCI Pharma Services

    Syngene

    Aphena Pharma Solutions

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Reed-Lane

    Adare Pharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Quality Risk Management

    It’s not just for the big guys anymore

    Quality Risk Management
    Quality Risk Management
    Quality Risk Management
    Quality Risk Management
    Related CONTENT
    • Mogene
    • Frontida BioPharm Launches Expansion Efforts
    • The FDA and Metrics
    • The Results Are In!
    • Domain, Pfizer in bioSensAll Alliance
    Emil W. Ciurczak, DoraMaxx Consulting04.03.17
    Having just attended IFPAC (International Forum Process Analytical Technology) in Maryland and then PittCon in Chicago, I had the opportunity to speak with the “movers and shakers” of the Pharma industry. There are several things upon which they agree: 1) continuous manufacturing (CM), including 3-D printing, is the future of pharmaceuticals; and 2) even the biggest name manufacturers are moving towards becoming “virtual” companies. Becoming virtual means that Big Pharma is shrinking—not in profits, just headcount. That is, they are, more and more, moving to outsourcing in clinical trials, manufacturing, and packaging while enhancing their core. Even the pure research is being augmented by university research and smaller, independent Pharma companies, so the future will look far different from the past.

    Now that Big Pharma is seeking partners for the grunt work (i.e., CROs, S+CMOs, and generic partners), the contract world needs to embrace a new paradigm and see it as a boon to the bottom line. To attract new monies from clients, we need to embrace the quote from Field of Dreams: “If you build it, he will come.” The tried and true approach of transferring production from the parent company to the contract manufacturing organization (CMO) will need to be updated. No longer will having mirror hardware of mixers, granulators, and tablet presses be sufficient. Since most of the larger companies (e.g., Pfizer, GSK, Merck, and Novartis) are embracing CM, having 1980s equipment is not what will attract new business. But, as I mentioned the hardware needs previously, I would like to address the other elephant in the room: building a QRM—needed for PAT and QbD—in a small company.

    What, you might ask, is QRM? Quality Risk Management is, in its simplest form, a mindset and atmosphere where we learn what could possibly go wrong and proceed to address it. Notice I did not say “fix,” just “address.” A properly designed and well-oiled QRM program follows the adage, “Let me fix what I can, accept what I can’t, and the wisdom to know which is which.” One of the questions that must be asked and seldom is by newcomers to the QRM field is, “Will fixing the problem cause more harm than good?”

    The FDA certainly believes QRM is key and the agency represented half the speakers in the dedicated sessions. Clearly, the large Pharma and BioPharma companies take it seriously and understand it is key to successful PAT/QbD programs. Now, we need to familiarize the CMOs and CROs with the need and relative simplicity of managing risk. Simple? Well, simple is relative. When the concept of QRM was advanced by the FDA and ICH, there were few software tools on the market to help. Over the last few years, any number of software packages have been released to the market. These range from bullet types—individual pieces, such as Ishakawa fishbone charts, numerous models of ranking risks such as FMEA, and design of experiment (DoE) software—to combinations of the pieces.

    Several companies who make larger statistical packages (e.g., CAMO and Umetrics, now MKS) also make DoE programs. Most are quite useful, if not specialized. Other, smaller packages are also available, where just Ishikawa (fishbone) diagrams, where all steps and sub-steps are graphed to more easily ascertain what could possibly contribute to a poorly behaving product (see Figure 1). An alternate way of displaying these points of potential risk is a simple block diagram (Figure 2), where each step of a batch process—easily converted to CM process—is a shopping list of contributions/parts in that step.

    While many larger companies have full-time staff to perform QRM programs, smaller companies may have to enlist part-timers or consultants to perform theirs. However, after seeing and participating in several exercises, the staff of these companies should be able to perform this on their own from there on. The most difficult part, in my opinion, is building risk values. Each small step is evaluated for three attributes: 1) How serious is any occurrence?; 2) What are its chances of occurring?; and 3) How easily can we detect it? Usually this is displayed as a couple of charts where each is paired off with one of the others (see Figure 3).

    These values for occurrence/seriousness/detectability can also be displayed on a single graph as seen in Figure 4. These values (ranging from 1-10) are placed into the ranking chart, often a FMEA program. The software can then represent the risks from highest to lowest and suggest which parameters to use in a formal DoE.

    Normally, these different steps may be purchased as smaller, individual software programs. And, just about any vendor’s works as advertised. However, the simpler the program, the more skill/experience is needed by the operator of that program. In a large, established organization, this is usually no problem. But, in a CMO/generic firm, the “warm bodies” are seldom just sitting in the break room, waiting to be consulted. But, do not fret. Newer, more operator friendly programs are being written and sold, even as we speak. One such package was shown at IFPAC this year.

    Named iRISK it was designed to ensure the organization follows proper, pre-defined sequences of risk management steps that include:

    Quality Target Product Profile (QTPP); Process Mapping; Cause-Effect Analysis; Failure Modes and Effects Analysis (FMEA); and on to DoE.

    It takes advantage of the linkage between the QRM tools available in the package to minimize re-work and boost risk-based decisions. These “workflows” are configured by the organization for the several Lifecycle stages of products/processes, as well as equipment and suppliers, to ensure the best fit with all QRM activities.

    When setting up the program, the block (step-wise) diagram is used. Clicking on each step provides a pull-down list of contributions. This is where your consultants or in-house staff insert all the steps affecting the particular stage of the process (e.g., for raw materials: density, particle size, moisture, flowability, crystallinity, or polymorphic form).

    When these boxes are populated, a click will convert the block diagram to an Ishakawa chart. When this “fishbone” presentation is satisfactory, a FMEA-type chart is automatically populated. The “experts” then use the values for each step based on severity, occurrence, and detectability to give them numerical values. These values are then converted to a Pareto chart for determination of which parameters should be evaluated in a DoE.

    What I liked about this package is that a small, less experienced company doesn’t need to purchase several programs or lean quite so much on consultants to succeed in developing a QRM program, which places them on par to succeed in gathering more contract manufacturing work from the “big guys.”

    Live long and prosper.
    Related Searches
    • Clinical Trials
    • Manufacturing
    • it
    • software
    Suggested For You
    Mogene Mogene
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    The FDA and Metrics The FDA and Metrics
    The Results Are In! The Results Are In!
    Domain, Pfizer in bioSensAll Alliance   Domain, Pfizer in bioSensAll Alliance
    Trump Picks New FDA Commish Trump Picks New FDA Commish
    Newsmakers: Bill Mitchell Newsmakers: Bill Mitchell
    Generic Drug Trends Generic Drug Trends
    Whither Washington? Whither Washington?
    Oral Solid Dosage Outsourcing: Trends & Challenges Oral Solid Dosage Outsourcing: Trends & Challenges
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    3D Printing Meets Pharma: Reward & Risk 3D Printing Meets Pharma: Reward & Risk
    Navigating the Shifting Landscape of Contract API Manufacturing Navigating the Shifting Landscape of Contract API Manufacturing
    FDA’s Quality Agreements Guidance FDA’s Quality Agreements Guidance
    Trends Affecting the Generic Drugs Sector in 2017 Trends Affecting the Generic Drugs Sector in 2017

    Related Columns

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Analytical Services | Laboratory Testing
      Re-Open Your Tool Chest

      Re-Open Your Tool Chest

      There’s no longer an excuse NOT to start “PAT-ing” your products
      Emil W. Ciurczak, DoraMaxx Consulting 07.15.19


    • Analytical Services | Laboratory Testing
      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker

      Making a solid case for PAT, QbD and continuous manufacturing in the pharma industry
      Emil W. Ciurczak, DoraMaxx Consulting 03.06.19

    • Analytical Services | Laboratory Testing
      The Great Diaspora of the Pharma Industry

      The Great Diaspora of the Pharma Industry

      Or, good things come in small(er) packages
      Emil W. Ciurczak, DoraMaxx Consulting 11.14.18

    • Analytical Services | Laboratory Testing
      Possibly Time for a New Paradigm

      Possibly Time for a New Paradigm

      Or, why the chicken should cross the road
      Emil W. Ciurczak, DoraMaxx Consulting 10.10.18


    • Analytical Services | Laboratory Testing
      The Times, They Are a-Changin’

      The Times, They Are a-Changin’

      For contract organizations and generics, for sure
      Emil W. Ciurczak, DoraMaxx Consulting 07.20.18

    • Analytical Services | Bioanalytical Services | Laboratory Testing
      The Final Frontier

      The Final Frontier

      A look at contract bioprocessing and PAT/QbD
      Emil W. Ciurczak, DoraMaxx Consulting 06.12.18

    • Analytical Services | Laboratory Testing
      We Need to Get Back to Basics

      We Need to Get Back to Basics

      In life, and the lab, the calculator/computer is a blessing and a curse!
      Emil W. Ciurczak, DoraMaxx Consulting 05.08.18


    • Analytical Services
      Finding the “Missing Link”

      Finding the “Missing Link”

      Outsourcing and the supply chain
      Emil W. Ciurczak, DoraMaxx Consulting 10.11.17

    • Analytical Services | Laboratory Testing
      Analytical Equipment Technology for the 21st Century

      Analytical Equipment Technology for the 21st Century

      A look at some more toys available for CMOs, CROs and generics to boost their analytical capabilities
      Emil W. Ciurczak, DoraMaxx Consulting 05.09.17

    • Analytical Services | R&D
      Trends in Pharma Analysis

      Trends in Pharma Analysis

      A look at how pharma analysis technology continues to evolve to meet market needs
      Emil W. Ciurczak, DoraMaxx Consulting 03.07.17


    • Analytical Services | Drug Development | Laboratory Testing

      Orphan Drug Development & Production: Turning Lemons into Lemonade

      Forming a “win-win-win” paradigm for large pharma companies, contract service providers and generics
      Emil W. Ciurczak, DoraMaxx Consulting 01.26.17

    • Analytical Services | Bioanalytical Services | Chemistry | Laboratory Testing

      Hyperspectral Imaging

      It’s not just for the Big Boys anymore
      Emil W. Ciurczak, DoraMaxx Consulting 11.09.16

    • Analytical Services | Bioanalytical Services | R&D

      Raman Spectroscopy

      Rapidly becoming the CRO/CMO’s best friend
      Emil W. Ciurczak, DoraMaxx Consulting 10.13.16

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Executive Moves: Novavax
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Ensuring Pharma Manufacturing Quality
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login